Assessing GR Life Style’s Valuation As It Pursues An AI Healthcare Transformation With Mingzhi Medical

GR Life Style’s pivot toward AI healthcare

GR Life Style (SEHK:108) has signed a cooperation memorandum with Mingzhi Medical Technology, aiming to link AI with oncology research and traditional Chinese medicine as it pivots away from a purely property-focused model.

See our latest analysis for GR Life Style.

The cooperation news comes after a sharp 32.14% 90-day share price return and a 9.75% 30-day share price return to HK$2.59. The 1-year total shareholder return of about 2.5x suggests strong momentum rather than a short-lived spike.

If this AI healthcare pivot has caught your attention and you want to see what else is changing quickly in the sector, now could be a good time to look at healthcare stocks.

After a 1-year total shareholder return of about 2.5x, a recent 90-day gain of 32.14% and a reported intrinsic discount of roughly 22%, it is reasonable to ask whether there is still an opportunity here or whether the market is already pricing in future growth.

Preferred Price-to-Sales of 27.6x: Is it justified?

On the latest figures, GR Life Style is trading on a P/S of 27.6x, which sits against a last close of HK$2.59 and points to a rich valuation compared with peers.

The P/S ratio compares a company’s market value with its revenue, so a higher figure usually means investors are paying more for each dollar of sales. For a business still rooted in property management and development and currently unprofitable, such a high P/S suggests the market may be focusing more on potential future revenue stories, including the AI healthcare angle, rather than on current financials.

That premium stands out sharply next to the Hong Kong Real Estate industry average P/S of 0.7x and a peer average of 2.1x. This means the market is valuing GR Life Style’s sales at a level many times higher than sector norms.

See what the numbers say about this price — find out in our valuation breakdown.

Result: Price-to-Sales of 27.6x (OVERVALUED)

However, you also have to weigh the company’s current loss of HK$916.692 and its lack of visible revenue or net income growth data against that rich P/S story.

Find out about the key risks to this GR Life Style narrative.

Another View: DCF flags a steep premium

Our DCF model paints a very different picture, with an estimated future cash flow value of HK$0.11 per share versus the current HK$2.59. That implies GR Life Style is trading at a very large premium. So is the market overpaying for the AI healthcare story?

Look into how the SWS DCF model arrives at its fair value.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out GR Life Style for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 873 undervalued stocks based on their cash flows. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Build Your Own GR Life Style Narrative

If you see the numbers differently or prefer to piece together your own view from the raw figures, you can build a custom narrative in just a few minutes by starting with Do it your way.

A great starting point for your GR Life Style research is our analysis highlighting 2 important warning signs that could impact your investment decision.

Ready to hunt for more ideas?

If GR Life Style has sparked your interest, do not stop here. The market is full of other angles you can assess with a clear, numbers first view.

• Spot potential value opportunities by checking out these 873 undervalued stocks based on cash flows that might offer more attractive cash flow based pricing.
• Tap into the next wave of tech-driven growth by scanning these 25 AI penny stocks that are tied to artificial intelligence themes.
• Target income focused ideas by reviewing these 13 dividend stocks with yields > 3% that currently offer yields above 3%.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com